Polarization and β-Glucan Reprogram Immunomodulatory Metabolism in Human Macrophages and Ex Vivo in Human Lung Cancer Tissues
Open Access
- 1 November 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (9) , 1674-1690
Abstract
Immunomodulatory (IM) metabolic reprogramming in macrophages (Mϕs) is fundamental to immune function. However, limited information is available for human Mϕs, particularly in response plasticity, which is critical to understanding the variable efficacy of immunotherapies in cancer patients. We carried out an in-depth analysis by combining multiplex stable isotope-resolved metabolomics with reversed phase protein array to map the dynamic changes of the IM metabolic network and key protein regulators in four human donors’ Mϕs in response to differential polarization and M1 repolarizer β-glucan (whole glucan particles [WGPs]). These responses were compared with those of WGP-treated ex vivo organotypic tissue cultures (OTCs) of human non-small cell lung cancer. We found consistently enhanced tryptophan catabolism with blocked NAD+ and UTP synthesis in M1-type Mϕs (M1-Mϕs), which was associated with immune activation evidenced by increased release of IL-1β/CXCL10/IFN-γ/TNF-α and reduced phagocytosis. In M2a-Mϕs, WGP treatment of M2a-Mϕs robustly increased glucose utilization via the glycolysis/oxidative branch of the pentose phosphate pathway while enhancing UDP-N-acetyl-glucosamine turnover and glutamine-fueled gluconeogenesis, which was accompanied by the release of proinflammatory IL-1β/TNF-α to above M1-Mϕ’s levels, anti-inflammatory IL-10 to above M2a-Mϕ’s levels, and attenuated phagocytosis. These IM metabolic responses could underlie the opposing effects of WGP, i.e., reverting M2- to M1-type immune functions but also boosting anti-inflammation. Variable reprogrammed Krebs cycle and glutamine-fueled synthesis of UTP in WGP-treated OTCs of human non-small cell lung cancer were observed, reflecting variable M1 repolarization of tumor-associated Mϕs. This was supported by correlation with IL-1β/TNF-α release and compromised tumor status, making patient-derived OTCs unique models for studying variable immunotherapeutic efficacy in cancer patients.Keywords
Funding Information
- HHS | NIH | National Cancer Institute (P01CA163223-01A1, 1R01CA118434-01A2, P30CA177558)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (1U24DK097215-01A1)
- HHS | NIH | National Institute of Environmental Health Sciences (5R21ES025669-02, 5R01ES22191)
- HHS | NIH | National Institute of General Medical Sciences (5P20GM121327)
This publication has 103 references indexed in Scilit:
- Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid productionProceedings of the National Academy of Sciences, 2013
- The Sedoheptulose Kinase CARKL Directs Macrophage Polarization through Control of Glucose MetabolismCell Metabolism, 2012
- Stable isotope-resolved metabolomics and applications for drug developmentPharmacology & Therapeutics, 2012
- High information throughput analysis of nucleotides and their isotopically enriched isotopologues by direct-infusion FTICR-MSMetabolomics, 2011
- Macrophage Expression of Hypoxia-Inducible Factor-1α Suppresses T-Cell Function and Promotes Tumor ProgressionCancer Research, 2010
- Alternative Activation of Macrophages: Mechanism and FunctionsImmunity, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Correcting for the effects of natural abundance in stable isotope resolved metabolomics experiments involving ultra-high resolution mass spectrometryBMC Bioinformatics, 2010
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1Journal of Experimental Medicine, 2009
- Altered macrophage differentiation and immune dysfunction in tumor developmentJournal of Clinical Investigation, 2007